Progress in biosimilar monoclonal antibody development: The infliximab biosimilar CT-P13 in the treatment of rheumatic diseases

Immunotherapy

Volumn 7, Issue 2, 2015, Pages 73-87

  Braun, Jürgen ^a   Kudrin, Alex ^b  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b Celltrion Inc   (South Korea)

Author keywords

ankylosing spondylitis; biosimilar; efficacy; immunogenicity; infliximab; rheumatoid arthritis; safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOSIMILAR AGENT; CT P 13; INFLIXIMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CT-P13; MONOCLONAL ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; LATENT TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; URINARY TRACT INFECTION; ANIMAL; ARTHRITIS, RHEUMATOID; BLOOD; DRUG APPROVAL; EUROPEAN UNION; SPONDYLITIS, ANKYLOSING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; EUROPEAN UNION; HUMANS; INFLIXIMAB; SPONDYLITIS, ANKYLOSING;

EID: 84923882220     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.109     Document Type: Review

References (53)

1. Agarwal SK. Core management principles in rheumatoid arthritis to help managed care professionals. Manag. Care Pharm. 17(9-b), S3-S8 (2011).
2. Colbert R. Biosimilars: the debate continues. Arthritis Rheum. 63(10), 2848-2850 (2011).
3. IMS Institute for Health Care Informatics. The global use of medicines: Outlook Through 2016. www.imshealth.com
4. Woodcock J, Griffin J, Behrman R et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat. Rev. Drug. Discov. 6, 437-442 (2007).
5. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res. Ther. 13, 112 (2011).
6. Dranitsaris G, Amir E et al. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 71, 1527-1536 (2011).
7. Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin. Exp. Rheumatol. 30(4 Suppl. 73), S102-S106 (2012).
8. Kudrin A. Overview of biosimilars: strategic considerations of various issues. J. Generic Med. 9(4), 187-206 (2012).
9. Shiestl M, Stangler T, Torella C et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat. Biotechnol. 29, 310-312 (2011).
10. Doerner T, Strand V, Castaneda-Hernandez G et al. The role of biosimilars in the treatment of rheumatic diseases. Ann. Rheum. Dis. 72(3), 322-328 (2013).
11. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann. Rheum. Dis. 72(10), 1589-1593 (2013).
12. Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-up protein drugs. N. Engl. J. Med. 358, 843-849 (2008).
13. WHO. Guidelines on evaluation of similar biotherapeutic products (SBPs). www.who.int
14. EMA. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Draft (2013). www.ema.europa.eu
15. EMA. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Inflectra (infliximab) (2013). www.ema.europa.eu
16. US FDA. Quality considerations in demonstrating biosimilarity to a reference protein product: draft guidance (2012). www.fda.gov
17. Siddiqui MAA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 65, 2179-2208 (2005).
18. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 6, 359 (9313), 1187-1193 (2002).
19. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin. Pharmacokinet. 46(8), 645-660 (2007).
20. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72(10), 1605-1612 (2013).
21. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis. 72(10), 1613-1620 (2013).
22. Park W, Jaworski J, Brzezicki J et al. A randomised, double-blind, parallel-group, Phase 1 study comparing the pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the PLANETAS study. Presented at: 14th Annual Congress of the European League Against Rheumatism. Madrid, Spain, 12-15 June 2013 (Abstract no. FRI0421).
23. Yoo DH, Racewicz A, Brzezicki J et al. A Phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Presented at: 14th Annual Congress of the European League Against Rheumatism. Madrid, Spain, 12-15 June 2013 (Abstract no. OP0068).
24. Park W, Miranda P, Brzosko M et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Presented at: ACR/ARHP Annual Meeting. San Diego, CA, USA, 26-30 October 2013 (Abstract no. L15).
25. Yoo DH, Prodanavic N, Jaowrski J et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Presented at: ACR/ARHP Annual Meeting. San Diego, CA, USA, 26-30 October 2013 (Abstract no. L15).
26. Barkham N, Keen HI, Coates LC et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 60(4), 946-954 (2009).
27. Sieper J, Lenaerts J, Wollenhaupt J et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann. Rheum. Dis. 73(1), 101-107 (2014) (2013).
28. Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis 5(5), 561-574 (2013).
29. EMA. Remsima: summary of product characteristics (2013). www.ema.europa.eu
30. EMA. Inflectra: summary of product characteristics (2013). www.ema.europa.eu
31. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343(22), 1594-1602 (2000).
32. St Clair EW, Van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004).
33. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
34. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350, 876-885 (2004).
35. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005).
36. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52(2), 582-591 (2005).
37. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52(4), 1227-1236 (2005).
38. Antoni CE, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64, 1150-1157 (2005).
39. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51(4), 534-542 (2004).
40. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 366(9494), 1367-1374 (2005).
41. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132(3), 863-873 (2007).
42. Hyams J, Damaraju L, Blank M et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 10(4), 391-399 (2012).
43. Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. 73, 198-206 (2014).
44. Putrik P, Ramiro S, Kvien TK et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Ann. Rheum. Dis. 73(11), 2010-2021 (2013).
45. Brodszky V, Pentek M, Baji P et al. Budget impact analysis of biosimilar infliximab treatment for rheumatoid arthritis in six Central European countries (Abstract no. PMS21). Value Health 16(7), A558 (2013).
46. McCarthy G, Ebel Bitoun C, Guy H. Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health 16(7), Abstract PMS22 (2013).
47. Devlin S et al. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can. J. Gastroenterol. 27(10), 567-571 (2013).
48. Kurki P, Bielsky M. ECCO position challenged by European drug regulators. J. Crohn's Colitis 8, 258 (2014).
49. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J. Crohn's Colitis 7, 586-589 (2013).
50. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5), 1088-1094 (2001).
51. Brandt J, Khariouzov A, Listing J et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48(6), 1667-1675 (2003).
52. Macdougall IC. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr. Med. Res. Opin. 20(1), 83-86 (2004).
53. Vermeire S, Gils A. Value of drug level testing and antibody assays in optimising biological therapy. Gastroenterology 4, 41-43 (2013).